Clustering analysis of total and active RNAP II at genes during the transition from G1 to G2. by Douglas Maya-Miles (7024967)

Data Sheet 1_A comparative analysis of cluster based interventions on healthcare-associated infections in a tertiary care hospital in China.doc by Ya Zou (6527423)

“…Additionally, a notable decrease in NSIs per 10,000 patient days was observed during the same comparison period, with a statistically significant difference (12.17 ± 1.47 vs. 9.20 ± 1.07, p = 0.006).…”

Changes in (A) Deaths and (B) DALYs of pancreatitis due to alcohol use according to aging, population growth and epidemiological change from 1990 to 2021 at global level by SDI qui... by Letai Li (19229848)

Identification of narciclasine as a novel NRF2 inhibitor by Hoang Hai Ngo (20564072)

“…Finally, we observed that administration of narciclasine significantly decreased the growth of A549 xenografts. …”

Table 1_Bifidobacterium compound preparations as a supplementary treatment for severe ischemic stroke: a systematic review and meta-analysis.docx by Shenghua Lu (20762612)

“…Regarding immune function, the BCP combination group significantly increased IgA (MD = 0.50, 95% CI 0.36 to 0.63, p < 0.00001) and IgG (MD = 3.00, 95% CI 2.03 to 3.97, p < 0.00001). …”

Profile of study locations and participants. by Hammed O. Mogaji (9421930)

“…Data analysis was conducted using R software version 4.3.2, with a 95% confidence interval.</p><p>Principal findings/conclusions</p><p>The parasitological data indicated a significant decline in the aggregated prevalence of STH across the three IUs. …”

Details of intervention by groups. by Payal Seth (20797011)

“…<div><p>Background</p><p>Open defecation (OD) remains a significant public health challenge in India, contributing to adverse child health outcomes. …”

Treatment impacts on hygiene behavior. by Payal Seth (20797011)

“…<div><p>Background</p><p>Open defecation (OD) remains a significant public health challenge in India, contributing to adverse child health outcomes. …”

Absolute β convergence results. by Ke Liu (121889)

“…The results revealed that from 2010 to 2020, the population agglomeration level of the Xi’an metropolitan area showed a trend of first increasing and then decreasing. …”

Conditional β convergence results. by Ke Liu (121889)

“…The results revealed that from 2010 to 2020, the population agglomeration level of the Xi’an metropolitan area showed a trend of first increasing and then decreasing. …”

Markov transition probability matrix (k = 4). by Ke Liu (121889)

“…The results revealed that from 2010 to 2020, the population agglomeration level of the Xi’an metropolitan area showed a trend of first increasing and then decreasing. …”

Markov transition probability matrix (k = 4). by Ke Liu (121889)

“…The results revealed that from 2010 to 2020, the population agglomeration level of the Xi’an metropolitan area showed a trend of first increasing and then decreasing. …”

Regression results. by Ke Liu (121889)

“…The results revealed that from 2010 to 2020, the population agglomeration level of the Xi’an metropolitan area showed a trend of first increasing and then decreasing. …”

Dynamic network effects of left DLPFC-tDCS protocol (F3a-Fp2c) with a sliding window length of 30 TRs. by Yanqing Dong (8829548)

“…Warmer colors indicate an increase in FC, while cooler colors indicate a decrease in FC. Color bars indicate statistical t-values (<i>p</i> < 0.05).…”

Dynamic network effects of left DLPFC-tDCS protocol (F3a-Fp2c) with a sliding window length of 50 TRs. by Yanqing Dong (8829548)

“…Warmer colors indicate an increase in FC, while cooler colors indicate a decrease in FC. Color bars indicate statistical t-values (<i>p</i> < 0.05).…”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”